Choose from Cassava Crop stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...

The Nigeria Natural Medicine Development Agency (NNMDA) has unveiled plans to train five million Nigerian youths in cassava cultivation through its Cassava Value Chain Initiative. Announcing the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials ...

Cassava Sciences ( (SAVA)) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cassava Sciences, Inc., a clinical-stage biotechnology ...

You need to Log in and be a client to access this file in full.

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam. The bull thesis hinges on simufilam outperforming current treatments or ...

Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest phase three trial goals on its Alzheimer's treatment drug, simufilam.